Dihydroergotamine mesylate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for dihydroergotamine mesylate and what is the scope of freedom to operate?
Dihydroergotamine mesylate
is the generic ingredient in five branded drugs marketed by Bausch, Hikma, Hikma Pharms, Padagis Us, Provepharm Sas, Sagent Pharms Inc, Amneal, Cipla, Impel Pharms, and Novartis, and is included in twelve NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Dihydroergotamine mesylate has sixty-one patent family members in fifteen countries.
There are six drug master file entries for dihydroergotamine mesylate. Eleven suppliers are listed for this compound.
Summary for dihydroergotamine mesylate
International Patents: | 61 |
US Patents: | 6 |
Tradenames: | 5 |
Applicants: | 10 |
NDAs: | 12 |
Drug Master File Entries: | 6 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 16 |
Patent Applications: | 2,536 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for dihydroergotamine mesylate |
What excipients (inactive ingredients) are in dihydroergotamine mesylate? | dihydroergotamine mesylate excipients list |
DailyMed Link: | dihydroergotamine mesylate at DailyMed |
Recent Clinical Trials for dihydroergotamine mesylate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ache Laboratorios Farmaceuticos S.A. | Phase 3 |
Xijing Hospital | Phase 2/Phase 3 |
Satsuma Pharmaceuticals, Inc. | Phase 3 |
Pharmacology for dihydroergotamine mesylate
Drug Class | Ergotamine Derivative |
Medical Subject Heading (MeSH) Categories for dihydroergotamine mesylate
US Patents and Regulatory Information for dihydroergotamine mesylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Impel Pharms | TRUDHESA | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 213436-001 | Sep 2, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Cipla | DIHYDROERGOTAMINE MESYLATE | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 212907-001 | May 20, 2020 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
Bausch | D.H.E. 45 | dihydroergotamine mesylate | INJECTABLE;INJECTION | 005929-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for dihydroergotamine mesylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | See Plans and Pricing | See Plans and Pricing |
Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | See Plans and Pricing | See Plans and Pricing |
Bausch | MIGRANAL | dihydroergotamine mesylate | SPRAY, METERED;NASAL | 020148-001 | Dec 8, 1997 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dihydroergotamine mesylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3679971 | DISPOSITIF D'ADMINISTRATION DE MÉDICAMENT PAR VOIE NASALE (NASAL DRUG DELIVERY DEVICE) | See Plans and Pricing |
Russian Federation | 2741249 | НАКОНЕЧНИКИ ДЛЯ НАЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ (TIPS FOR NASAL DRUG DELIVERY) | See Plans and Pricing |
New Zealand | 741171 | In-line nasal delivery device | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.